Novartis Q2 profit rises 24% on strong U.S. sales of Kisqali and Entresto

Novartis reported strong second-quarter performance, with net income rising 24% to $4 billion and net sales increasing 12% to $14.1 billion, primarily fueled by significant growth in key therapies such as Kisqali (+64%) and Entresto (+24%) and robust U.S. market contribution. The company also saw a 29% increase in EPS to $2.07 and a 37% surge in free cash flow to $6.3 billion, alongside expanding operating margins. Despite the strong operational results, net debt climbed to $23.8 billion following substantial dividend payments and share buybacks.

Analysis

Novartis delivered a robust second quarter, characterized by significant top-line growth and margin expansion. Net sales grew 12% to $14.1 billion, propelled by a 21% surge in the U.S. market and strong volume growth of 12 percentage points, which successfully offset a 2-point drag from generic competition. This performance was driven by key therapies, with cancer drug Kisqali sales climbing 64% and heart failure treatment Entresto rising 24%. Profitability metrics were notably strong, with the operating income margin improving to 34.6% from 32.1% a year prior, and the core operating margin reaching 42.2%. This was achieved despite a 15% increase in R&D spending, reflecting effective cost management as cost of goods sold declined as a percentage of sales. Cash generation was a key highlight, with free cash flow increasing 37% to $6.3 billion. However, the balance sheet shows a significant increase in net debt to $23.8 billion from $16.1 billion, a direct result of substantial capital returns to shareholders, including $7.8 billion in dividends and $5.5 billion in share buybacks during the first half.

Key Decisions for Investors

• The strong top-line growth and margin expansion, driven by key products like Kisqali and Entresto, affirm the company's successful portfolio strategy, suggesting investors should maintain a constructive view on the stock's fundamental momentum.
• Investors should closely monitor the sales trajectory of the high-growth drugs, as their continued outperformance is critical to offsetting the predictable decline of established brands facing generic erosion.
• While substantial capital returns are attractive, the resulting increase in net debt to $23.8 billion warrants scrutiny; it is prudent to assess the sustainability of this level of shareholder payout against the company's long-term investment needs and financial flexibility.